H7N9 vaccine production fast-tracked

04/12/2013 | Reuters

Escalating concerns about the H7N9 influenza strain that has surfaced in China have prompted scientists to use new technology to create a viral seed strain, potentially shortening the development time for a vaccine. The approach, developed after the 2009 H1N1 pandemic, uses the genetic code of the virus, instead of a sample of the virus itself, to create synthetic DNA and manufacture the virus then used in vaccine development. The time saved could be critical, said Robin Robinson, director of the Biomedical Advanced Research and Development Authority.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC